Nexstim mainittu Iltalehdessä. Any publicity is good publicity
Nexstim lunastaa jo odotuksia
Kakkosen omistuksista terveysteknologiayhtiö Nexstimin osake on noussut vuoden alusta yli 70 prosenttia. Kakkosen mukaan Nexstimin tarina on vasta alussa.
– Yhdysvalloissa on avautumassa yhtiölle isoja mahdollisuuksia. Siellä on tehty hyvää, pitkäjänteistä työtä, ja itse tuote on hyvä. Vakavan masennuksen hoito on ihan oikeasti iso ongelma, ja näillä laitteilla Nexstim on johtava laitevalmistaja omalla sektorillaan, Kakkonen sanoo.
Does anyone know if there’s an upper limit to that portfolio curve? I guess I’ll have to buy a taller phone.. Köpi has Trump-like effects on the domestic stock market He could probably cause a discount dip with comments if he wanted to.
The exit will eventually come in one or more blocks; it’s difficult to offload such quantities with these trading volumes. But it might not come until a year or even more from now; no one knows that.
And talking about the price probably won’t help much in finding that single buyer. Well, of course, one can always say that I’d have a slightly larger batch for sale at 20e/piece if interested, etc.
But let’s wait and see; probably the H1 report next.
I haven’t even talked about anything like that, and I believe he wants more return, didn’t he get in when the price was quite high back then before these splits?
Here are the comments from the president of Brainlab on LinkedIn just now;
Vinicius Dessoy Maciel
I have been following how Nexstim nTMS combined with Brainlab Elements Fibertracking gives surgeons a much clearer understanding of key brain functions before surgery.
This detailed mapping helps protect critical motor areas and allows the surgeon to remove tumors more effectively.
As Professor Bernhard Meyer from TUM Klinikum Rechts der Isar said: “nTMS makes surgery safer, resection rates are higher, and ultimately, the outcomes are better.”
We are working with Nexstim and focusing on providing neurosurgical teams with accurate, patient-specific information to support their decisions in the operating room. It is rewarding to be part of a process that is shaping the future of brain surgery.
Want to learn more about how these tools are making an impact?
*The surgeon’s statement represents his personal opinion and experiences. This claim may not be supported by scientific evidence or peer-reviewed research. Please refer to the manufacturer’s official documents or clinical guidelines for verified information about the device.
Press release, Helsinki, 10 July 2025 at 9 AM (EEST)
Distributor Orders Nexstim NBS 6 System
Nexstim Plc (NXTMH:HEX) (“Nexstim” or “Company”) has received order for an NBS 6 system from a distributor. The end customer is a Nordic therapy clinic that is acquiring their first Nexstim system.
The NBS (Navigated Brain Stimulation) 6 is a new generation Nexstim system. Developed in collaboration with Nexstim’s customers, the NBS 6 system makes the Company’s clinically established, e-field navigated TMS (transcranial magnetic stimulation) technology more user-friendly than ever before. The NBS 6 system is currently CE-marked for the treatment of major depression and chronic neuropathic pain in the EU, and FDA-cleared for the treatment of major depressive disorder in the United States.
Mikko Karvinen, CEO of Nexstim, comments: “This new customer will use our system to treat both chronic neuropathic pain and major depression.
A syndrome of chronic neuropathic pain may develop after damage to nerves, due to accident, disease or even an amputation. Targeting rTMS, repetitive TMS, to the motor cortex, or related areas, has resulted in meaningful relief for some patients.
Nexstim NBS 6 for depression is intended to be used in adult patients who have failed to achieve satisfactory improvement from prior antidepressant medication in the current episode. Both our experienced and new customers have been excited about the new software, and many have already treated a great number of patients with the NBS 6.”
Further information is available on the website www.nexstim.com, or by contacting:
Do I understand correctly that this latest device is not included in the “warranty” price, because the treatment purpose is “depression and chronic neuropathic pain”.
It would be interesting to know what these new devices cost in total with training, modules, and maintenance contracts.
Probably some of the recurring revenue also goes into that 4 million, because maintenance contracts were also included in that, and I assume that maintenance contracts made in connection with the deal are part of recurring revenue.
I’ve been on a bit of a holiday, but now that I’ve opened my laptop again and put the announced deals into a table, I noticed that my gut feeling about the growth figures was wrong, and the actual growth is even greater!
Deals announced during the first half of 2024:
NBS5 mapping: 3 units
Combination device 5: 2 units
NBS 6 therapy: 1 unit Total 6 units
Deals announced during the first half of 2025:
NBS5 mapping: 1 unit
Combination device 5: 8 units
NBS 6 therapy: 2 units
Sinaptica: 1 unit + “several devices” Total: 12 units + “several devices”
So, even when calculated purely by the number of devices, growth is over 100%, but in 2025, sales have also focused more strongly on combination devices, so the revenue from device sales has likely grown even more in percentage terms than the number of units. Good momentum is ongoing, and it’s a pleasure to note that the pace is continuing in July as well. Last year in July, a total of 3 deals were announced, and now, on July 10th, 4 deals have already been announced.
And Finland was also excluded from the Brainlab agreement, and additionally, countries where Nexstim already had a distributor are observing a transition period (which are probably to be agreed upon per distributor?). So, it is not easy to estimate how much of the guaranteed amount has already accumulated this year.
He could probably cause a discount dip with comments if he wanted to.
Want to learn more about how these tools are making an impact?
